Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06183437 · ClinicalTrials.gov registry record · Phase 4
The STOP-MED CTRCD Trial
A Phase 4 study of Cancer and Heart Failure, sponsored by University Health Network, Toronto.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 335
- Enrollment target
- 10
- Study locations
NCT06183437 is a Phase 4 study of Cancer and Heart Failure that is actively recruiting participants, run by University Health Network, Toronto. The registered enrollment target is 335 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (90% lower). The trial reports 10 study locations across 6 states.
The verdict
NCT06183437, a Phase 4 study of Cancer and Heart Failure, is actively recruiting participants, sponsored by University Health Network, Toronto.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 335 participants
- Enrollment target
- 10
- Study locations
Study Summary
Cancer therapy-related cardiac dysfunction (CTRCD) is when the heart's ability to pump oxygenated blood to the body is compromised. It is a side effect of cancer therapy which can occur as commonly as in 1 in 5 patients. When this occurs, heart failure medications are started to protect the heart from progressing to heart failure. With early detection and treatment, heart function recovers to normal in \>80% of patients. Unfortunately, heart failure medications are associated with an undesirable long-term pill burden, financial costs, and side-effects (e.g., dizziness and fatigue). As a result, cancer survivors frequently ask if they can safely stop their heart failure medications once their heart function has returned to normal. Currently there is no scientific evidence in this area of Cardio-Oncology. To address this knowledge gap, the investigators have designed a randomized control trial to assess the safety of stopping heart failure medication in patients with CTRCD and recovered heart function. The investigators will enrol patients who have completed their cancer therapy and are on heart medications for their CTRCD, which has now normalized. The investigators will randomize patients with no other reasons to continue heart failure medications (e.g., kidney disease) to continuing or stopping their heart medications safely. All patients will undergo a cardiac MRI at baseline, 1 and 5 years with safety assessments at 6-8 weeks, 6 months and 3 and 5 years. The investigators will determine if stopping medications is non-inferior to continuing medications by counting the numbers of patients who develop heart dysfunction by 1 year in each group.
Conditions Studied
Interventions
- OTHER Stopping Heart Failure Medication(s)
Study Locations (10)
Ontario
- Hamilton General Hospital - Hamilton
- University of Ottawa Heart Institute - Ottawa
- St Michael's Hospital - Toronto
- University Health Network - Toronto
Alberta
- Foothills Medical Centre - Calgary
- Edmonton Clinic Health Academy - Edmonton
Massachusetts
- Brigham and Women's Hospital - Boston
Victoria
- Baker Heart and Diabetes Institute - Melbourne
Manitoba
- St. Boniface Hospital - Winnipeg
Other
- Barts Health NHS Trust, University College London - London
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 335 participants |
| Start Date | 2024-03-04 |
| Est. Completion | 2031-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06183437
The ClinicalTrials.gov registry entry for NCT06183437 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 335 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (90% lower). The listed sponsor is University Health Network, Toronto, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Cancer appearing as the primary indexed condition, and to 1 intervention - of which Stopping Heart Failure Medication(s) is the first listed.
NCT06183437 reports 10 study locations spanning 6 distinct geographic areas - top geographies include Ontario, Alberta, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06183437 about?
NCT06183437 is a clinical study titled "The STOP-MED CTRCD Trial". Cancer therapy-related cardiac dysfunction (CTRCD) is when the heart's ability to pump oxygenated blood to the body is compromised. It is a side effect of cancer therapy which can occur as commonly as in 1 in 5 patients. When this occurs, heart failure medications are started to protect the heart fr...
What is the current status of trial NCT06183437?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 335 participants. The study started on 2024-03-04. Estimated completion is 2031-12.
What conditions does trial NCT06183437 study?
This clinical trial studies the following conditions: Cancer, Heart Failure, Cardiotoxicity, Cardiac Toxicity, Antineoplastics Toxicity.
What interventions are being tested in trial NCT06183437?
The interventions under investigation include: Stopping Heart Failure Medication(s) (OTHER).
Who is sponsoring clinical trial NCT06183437?
This trial is sponsored by University Health Network, Toronto, which has 23 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06183437 being conducted?
This trial has 10 study locations across Massachusetts, Victoria, Alberta, Manitoba, Ontario. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluation of Dalteparin for Long-term (One Year) Treatment of Blood Clots in Subjects With Cancer
COMPLETED · Phase 4
-
Tobacco Treatment Comparison for Cancer Care
COMPLETED · Phase 4
-
Study Using the MedPulser Electroporation System With Bleomycin to Treat Cutaneous and Subcutaneous Cancer
COMPLETED · Phase 4
-
Registry Study to Evaluate the Clinical Outcome of Cancer Patients and Benign Diseases Treated with Radiation
RECRUITING
-
Treatment of Immune Checkpoint Inhibitor-related Diarrhea and/ or Colitis With Ustekinumab in Cancer Patients
RECRUITING · Phase 2
-
IMPACT (IMproving Proactive Approaches for Cancer Survivors' Mental Health Treatment)
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.